Compare Alphabet Inc Class A (GOOGL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Regeneron Pharmaceuticals Inc — how do they compare? Alphabet Inc Class A trades at $345.68 (market cap $4.20T), while Regeneron Pharmaceuticals Inc trades at $794.9 (market cap $82.06B). The key difference: Alphabet Inc Class A is far larger — about 51.2× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.47%). Which is the better fit depends on your goals.
| GOOGL | REGN | |
|---|---|---|
Market Cap | $4.20T | $82.06B |
Sector | Media | Health |
52-Week High | $402.62 | $812.27 |
52-Week Low | $199.32 | $555.51 |
Enterprise Value | $4.09T | $76.77B |
Dividend Yield | 0.26% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $357.52, up 0.91% today, with a bullish technical signal from moving averages and strong support at $354. The stock shows robust fundamentals, with revenue growing from $350.0B in 2024 to $402.8B in 2025 (SEC filings, 2025), net income margin expanding to 32.8%, and consistent earnings beats. Recent news highlights AI-driven growth opportunities, including partnerships and YouTube price increases (Reuters, 2026-04-10).
Outlook remains positive with an 85% analyst buy rating and $426.28 consensus price target (MarketBeat, 2026-04-11), though risks include antitrust scrutiny and tech sector volatility. Earnings growth and AI integration are key catalysts for upside, while competition and regulatory pressures warrant monitoring.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
